Functional Neuroimaging in depression: longitudinal study of PET metabolism in correlation with changes in attentional bias, autobiographical memory, future fluency and facial recognition in depressed patients treated with escitalopram

• Conditions: Major depression

• Registration Number: EUCTR2005-005739-91-BE
• Lead Sponsor: niversity Hospital Ghent

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05-24
• Last Update Posted: 7 October 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Major Depression, Depressive episode, following DSM-IV criteria (SCID-I)
MADRS-score > 25
Inpatients (at inclusion) and outpatients
Age: 18-65 yrs
Medication-free or Anti-depressant wash-out 7 days (fluoxetine 6 weeks)
Lorazepam 1mg or zolpidem 10mg are allowed

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Bipolar disorder, following DSM-IV criteria (SCID-I)
Personality disorder, following DSM-IV criteria (SCID-II)
Diabetes mellitus
Women without anticonceptive protection, pregnancy or breast feeding
Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion
Psychotic symptomsSubstance abuse
IQ below 80
Cognitive dysfunction due to trauma capitis or dementia

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To explore alterations in brain metabolism by means of 18F-FDG PET in relation to information processing ratings, in patients with major depression treated with 8 wks escitalopram;Secondary Objective: To explore cross-sectional differences in brain metabolism of depressed patients compared to healthy volunteers (normal database) before and after treatment with escitalopram<br>To explore the influence of 2 and 8 wks escitalopram treatment on information processing (attentional bias, autobiographical memory, future fluency, facial recognition) in patients with major depression<br>To explore the influence of 2 and 8 weeks escitalopram treatment on depression, anxiety and hopelessness ratings in patients with major depression <br>;Primary end point(s): To evaluate the effect of the antidepressant escitalopram on cognitive functions and brain metabolism in depressed patients.